|
시장보고서
상품코드
2023534
생명과학 애널리틱스용 AI 시장 분석 및 예측(-2035년) - 유형, 서비스, 기술, 용도, 도입 형태, 최종사용자AI in Life Science Analytics Market Analysis and Forecast to 2035: Type, Services, Technology, Application, Deployment, End User |
||||||
세계의 생명과학 애널리틱스용 AI 시장은 2025년 117억 달러에서 2035년까지 418억 달러로 성장하며, CAGR은 12.3%에 달할 것으로 예측됩니다. 도입 현황은 제약사 및 연구기관의 소프트웨어 라이선스 및 분석 워크로드를 통해 측정됩니다. SAS Institute, Oracle 등의 기업이 기업급 플랫폼을 제공하고 있습니다. 가격 설정은 보통 구독 방식으로 데이터 규모와 기능에 따라 연간 5만 달러에서 수백만 달러까지 다양합니다. 비용은 통합의 복잡성, 분석 기능, 규제 준수 요건에 따라 달라질 수 있습니다. 신약 개발 및 임상 연구에서의 AI 활용 확대가 전체 시장에서의 도입 확대와 지출 증가를 주도하고 있습니다.
생명과학 분석 시장에서 AI의 '유형' 부문은 주로 예측 분석이 주류를 이루고 있습니다. 이는 과거 데이터와 실시간 데이터를 이용하여 생물학적 결과, 약물 반응, 질병 진행을 예측할 수 있기 때문입니다. 이 기능은 성공률을 예측하여 시간과 비용을 크게 절감할 수 있는 신약개발 및 임상시험에서 매우 가치 있는 기능입니다. 또한 예측 분석에 기반한知見(지견)을 통해 최적의 행동을 추천하는 처방 분석도 주목받고 있습니다. 생물학적 데이터의 증가와 데이터에 기반한 의사결정의 필요성은 이 시장에서 고급 분석 기법의 성장을 이끄는 주요 요인입니다.
응용 분야는 신약 개발이 주도하고 있으며, 이는 새로운 치료제 개발을 가속화해야 할 필요성이 높아짐에 따라 주도하고 있습니다. AI를 활용한 분석은 신약 타겟 발굴, 분자간 상호작용 분석, 후보 화합물 선정 최적화에 도움을 주어 연구개발 기간과 비용을 절감할 수 있습니다. 임상시험도 주요 응용 분야 중 하나이며, AI는 피험자 모집, 시험 설계 및 결과 예측을 개선할 수 있습니다. 또한 생명과학 워크플로우의 효율성, 정확성 및 컴플라이언스 향상을 위한 AI 툴의 도입이 확대되고 있는 가운데, 전임상 연구 및 규제 준수에 대한 적용도 확대되고 있습니다.
지역별 개요
북미는 탄탄한 디지털 헬스 인프라, 첨단화된 AI 생태계, 제약 및 생명공학 기업의 높은 집중도로 인해 생명과학 분석 AI 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 미국은 신약개발, 임상시험, 약물감시, 정밀의학 분야에서 AI 기반 분석을 광범위하게 도입하여 이 지역을 선도하고 있습니다. 생명과학 기업 및 기술 제공업체들의 대규모 투자로 인해 머신러닝과 예측 분석이 연구 워크플로우에 통합되는 속도가 빨라지고 있습니다. 데이터베이스 헬스케어 혁신에 대한 강력한 규제적 지원과 주요 클라우드 및 AI 기업의 존재는 글로벌 시장에서 북미의 우위를 더욱 공고히 하고 있습니다.
아시아태평양은 의료 분야의 급속한 디지털 전환과 인공지능 및 생명공학에 대한 투자 확대로 인해 생명과학 분석 시장에서 AI 분야에서 가장 높은 CAGR을 기록할 것으로 예상됩니다. 중국, 인도, 일본, 한국 등의 국가들은 신약개발, 유전체학, 임상연구에 AI 도입을 적극적으로 추진하고 있습니다. 제약 제조의 확대, 임상 시험 활동의 증가, 의료 데이터의 가용성 증가가 고급 분석 솔루션에 대한 수요를 견인하고 있습니다. AI 혁신을 지원하는 정부의 노력과 바이오테크 스타트업과 글로벌 제약사들과의 협력 강화는 아시아태평양을 가장 빠르게 성장하는 지역 시장으로 성장시키고 있습니다.
주요 동향 및 촉진요인
데이터베이스 신약 개발 및 임상 의사결정에 대한 수요 증가
생명과학 분석 시장에서 AI의 주요 촉진요인은 신약 개발 및 임상 의사결정에 있으며, 데이터베이스 접근 방식에 대한 요구가 증가하고 있다는 점입니다. 기존의 연구 방법은 시간과 비용이 많이 들지만, AI를 활용하면 신약 후보물질의 신속한 발굴, 분자간 상호작용 예측, 임상시험 설계 최적화가 가능합니다. 제약사들은 연구개발의 효율성을 높이고 실패율을 낮추기 위해 머신러닝과 예측분석을 점점 더 많이 활용하고 있습니다. 유전체학, 단백질체학, 리얼월드에비던스(RWE)에서 얻은 바이오메디컬 데이터의 양이 증가하고 있는 것도 AI 도입을 더욱 촉진하고 있습니다. 이러한 요인들이 결합되어 전 세계 생명과학 연구 및 의료 애플리케이션에서 AI 기반 분석의 통합이 가속화되고 있습니다.
AI를 활용한 정밀의료 및 RWD(Real World Data) 분석의 확장
생명과학 분석 시장에서 AI의 주요 기회는 정밀의료와 RWD(Real World Data) 분석의 확대에 있습니다. AI 기술은 유전체학, 전자 건강 기록, 웨어러블 기기 입력 데이터를 포함한 대규모 환자 데이터를 통합하고 분석하여 고도로 개인화된 치료 전략을 개발할 수 있게 해줍니다. 규제 당국의 의사결정에 있으며, RWE(Real World Evidence)의 채택이 확대되면서 고급 분석 플랫폼에 대한 수요가 더욱 증가하고 있습니다. 또한 제약사, AI 스타트업, 의료 서비스 제공자 간의 파트너십이 혁신을 가속화하고 있습니다. 클라우드 기반 AI 플랫폼의 사용 확대는 확장성과 접근성을 향상시켜 글로벌 시장에서 장기적으로 큰 성장 기회를 창출하고 있습니다.
목차
제1장 개요
제2장 시장 하이라이트
제3장 시장 역학
제4장 부문 분석
제5장 지역별 분석
제6장 시장 전략
제7장 경쟁 정보
제8장 기업 개요
제9장 Global Insight Services 소개
KSAThe global AI in Life Science Analytics Market is projected to grow from $11.7 billion in 2025 to $41.8 billion by 2035, at a compound annual growth rate (CAGR) of 12.3%. Adoption is measured through software licenses and analytics workloads across pharmaceutical and research organizations. Companies like SAS Institute and Oracle provide enterprise-level platforms. Pricing is typically subscription-based, ranging from USD 50,000 to several million annually depending on data scale and functionality. Costs are influenced by integration complexity, analytics capabilities, and regulatory compliance requirements. Increasing use of AI in drug discovery and clinical research is driving higher adoption and spending across this market.
The Type segment in the AI in Life Science Analytics Market is primarily dominated by predictive analytics, as it enables forecasting of biological outcomes, drug responses, and disease progression using historical and real-time data. This capability is highly valuable in drug discovery and clinical trials, where predicting success rates can significantly reduce time and costs. Prescriptive analytics is also gaining traction by recommending optimal actions based on predictive insights. The increasing volume of biological data and the need for data-driven decision-making are key factors driving the growth of advanced analytics types in this market.
| Market Segmentation | |
|---|---|
| Type | Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Diagnostic Analytics |
| Services | Consulting, Implementation, Support and Maintenance |
| Technology | Machine Learning, Natural Language Processing, Computer Vision, Robotics |
| Application | Drug Discovery, Clinical Trials, Preclinical Research, Regulatory Compliance |
| Deployment | Cloud-Based, On-Premises, Hybrid |
| End User | Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations |
The Application segment is led by drug discovery, driven by the growing need to accelerate the development of new therapeutics. AI-powered analytics help in identifying drug targets, analyzing molecular interactions, and optimizing candidate selection, thereby reducing R&D timelines and costs. Clinical trials are another major application, where AI improves patient recruitment, trial design, and outcome prediction. Additionally, applications in preclinical research and regulatory compliance are expanding, supported by the increasing adoption of AI tools to enhance efficiency, accuracy, and compliance in life sciences workflows.
Geographical Overview
North America holds the largest market share in the AI in Life Science Analytics Market due to its strong digital health infrastructure, advanced AI ecosystem, and high concentration of pharmaceutical and biotechnology companies. The United States leads the region with extensive adoption of AI-driven analytics in drug discovery, clinical trials, pharmacovigilance, and precision medicine. Major investments from life science firms and technology providers are accelerating integration of machine learning and predictive analytics into research workflows. Strong regulatory support for data-driven healthcare innovation and the presence of leading cloud and AI companies further reinforce North America's dominant position in the global market.
Asia Pacific is expected to register the highest CAGR in the AI in Life Science Analytics Market due to rapid digital transformation in healthcare and increasing investments in artificial intelligence and biotechnology. Countries such as China, India, Japan, and South Korea are actively promoting AI adoption in drug discovery, genomics, and clinical research. Expanding pharmaceutical manufacturing, rising clinical trial activities, and growing availability of healthcare data are driving demand for advanced analytics solutions. Government initiatives supporting AI innovation and increasing collaborations between biotech startups and global pharma companies further accelerate growth, making Asia Pacific the fastest-growing regional market.
Key Trends and Drivers
Increasing demand for data-driven drug discovery and clinical decision-making
A key driver of the AI in Life Science Analytics Market is the rising need for data-driven approaches in drug discovery and clinical decision-making. Traditional research methods are time-consuming and costly, while AI enables faster identification of drug candidates, prediction of molecular interactions, and optimization of clinical trial design. Pharmaceutical companies are increasingly leveraging machine learning and predictive analytics to enhance R&D efficiency and reduce failure rates. The growing volume of biomedical data from genomics, proteomics, and real-world evidence is further driving adoption. These factors collectively accelerate the integration of AI-powered analytics across life sciences research and healthcare applications globally.
Expansion of AI-enabled precision medicine and real-world data analytics
A major opportunity in the AI in Life Science Analytics Market lies in the expansion of precision medicine and real-world data analytics. AI technologies enable the integration and analysis of large-scale patient data, including genomics, electronic health records, and wearable device inputs, to develop highly personalized treatment strategies. Increasing adoption of real-world evidence in regulatory decision-making is further boosting demand for advanced analytics platforms. Additionally, partnerships between pharmaceutical companies, AI startups, and healthcare providers are accelerating innovation. The growing use of cloud-based AI platforms enhances scalability and accessibility, creating significant long-term growth opportunities in the global market.
Research Scope
- Estimates and forecasts the overall market size across type, application, and region.
- Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
- Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
- Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
- Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
- Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
- Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.
TABLE OF CONTENTS
1 Executive Summary
- 1.1 Market Size and Forecast
- 1.2 Market Overview
- 1.3 Market Snapshot
- 1.4 Regional Snapshot
- 1.5 Strategic Recommendations
- 1.6 Analyst Notes
2 Market Highlights
- 2.1 Key Market Highlights by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics, Diagnostic Analytics)
- 2.2 Key Market Highlights by Services (Consulting, Implementation, Support and Maintenance)
- 2.3 Key Market Highlights by Technology (Machine Learning, Natural Language Processing, Computer Vision, Robotics)
- 2.4 Key Market Highlights by Application (Drug Discovery, Clinical Trials, Preclinical Research, Regulatory Compliance)
- 2.5 Key Market Highlights by Deployment (Cloud-Based, On-Premises, Hybrid)
- 2.6 Key Market Highlights by End User (Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations)
3 Market Dynamics
- 3.1 Macroeconomic Analysis
- 3.2 Market Trends
- 3.3 Market Drivers
- 3.4 Market Opportunities
- 3.5 Market Restraints
- 3.6 CAGR Growth Analysis
- 3.7 Impact Analysis
- 3.8 Emerging Markets
- 3.9 Technology Roadmap
- 3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis
4 Segment Analysis
- 4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Descriptive Analytics
- 4.1.2 Predictive Analytics
- 4.1.3 Prescriptive Analytics
- 4.1.4 Diagnostic Analytics
- 4.2 Market Size & Forecast by Services (2020-2035)
- 4.2.1 Consulting
- 4.2.2 Implementation
- 4.2.3 Support and Maintenance
- 4.3 Market Size & Forecast by Technology (2020-2035)
- 4.3.1 Machine Learning
- 4.3.2 Natural Language Processing
- 4.3.3 Computer Vision
- 4.3.4 Robotics
- 4.4 Market Size & Forecast by Application (2020-2035)
- 4.4.1 Drug Discovery
- 4.4.2 Clinical Trials
- 4.4.3 Preclinical Research
- 4.4.4 Regulatory Compliance
- 4.5 Market Size & Forecast by Deployment (2020-2035)
- 4.5.1 Cloud-Based
- 4.5.2 On-Premises
- 4.5.3 Hybrid
- 4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Pharmaceutical Companies
- 4.6.2 Biotechnology Companies
- 4.6.3 Research Institutes
- 4.6.4 Contract Research Organizations
5 Regional Analysis
- 5.1 Global Market Overview
- 5.2 North America Market Size (2020-2035)
- 5.2.1 United States
- 5.2.1.1 Type
- 5.2.1.2 Services
- 5.2.1.3 Technology
- 5.2.1.4 Application
- 5.2.1.5 Deployment
- 5.2.1.6 End User
- 5.2.2 Canada
- 5.2.2.1 Type
- 5.2.2.2 Services
- 5.2.2.3 Technology
- 5.2.2.4 Application
- 5.2.2.5 Deployment
- 5.2.2.6 End User
- 5.2.3 Mexico
- 5.2.3.1 Type
- 5.2.3.2 Services
- 5.2.3.3 Technology
- 5.2.3.4 Application
- 5.2.3.5 Deployment
- 5.2.3.6 End User
- 5.2.1 United States
- 5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
- 5.3.1.1 Type
- 5.3.1.2 Services
- 5.3.1.3 Technology
- 5.3.1.4 Application
- 5.3.1.5 Deployment
- 5.3.1.6 End User
- 5.3.2 Argentina
- 5.3.2.1 Type
- 5.3.2.2 Services
- 5.3.2.3 Technology
- 5.3.2.4 Application
- 5.3.2.5 Deployment
- 5.3.2.6 End User
- 5.3.3 Rest of Latin America
- 5.3.3.1 Type
- 5.3.3.2 Services
- 5.3.3.3 Technology
- 5.3.3.4 Application
- 5.3.3.5 Deployment
- 5.3.3.6 End User
- 5.3.1 Brazil
- 5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
- 5.4.1.1 Type
- 5.4.1.2 Services
- 5.4.1.3 Technology
- 5.4.1.4 Application
- 5.4.1.5 Deployment
- 5.4.1.6 End User
- 5.4.2 India
- 5.4.2.1 Type
- 5.4.2.2 Services
- 5.4.2.3 Technology
- 5.4.2.4 Application
- 5.4.2.5 Deployment
- 5.4.2.6 End User
- 5.4.3 South Korea
- 5.4.3.1 Type
- 5.4.3.2 Services
- 5.4.3.3 Technology
- 5.4.3.4 Application
- 5.4.3.5 Deployment
- 5.4.3.6 End User
- 5.4.4 Japan
- 5.4.4.1 Type
- 5.4.4.2 Services
- 5.4.4.3 Technology
- 5.4.4.4 Application
- 5.4.4.5 Deployment
- 5.4.4.6 End User
- 5.4.5 Australia
- 5.4.5.1 Type
- 5.4.5.2 Services
- 5.4.5.3 Technology
- 5.4.5.4 Application
- 5.4.5.5 Deployment
- 5.4.5.6 End User
- 5.4.6 Taiwan
- 5.4.6.1 Type
- 5.4.6.2 Services
- 5.4.6.3 Technology
- 5.4.6.4 Application
- 5.4.6.5 Deployment
- 5.4.6.6 End User
- 5.4.7 Rest of APAC
- 5.4.7.1 Type
- 5.4.7.2 Services
- 5.4.7.3 Technology
- 5.4.7.4 Application
- 5.4.7.5 Deployment
- 5.4.7.6 End User
- 5.4.1 China
- 5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
- 5.5.1.1 Type
- 5.5.1.2 Services
- 5.5.1.3 Technology
- 5.5.1.4 Application
- 5.5.1.5 Deployment
- 5.5.1.6 End User
- 5.5.2 France
- 5.5.2.1 Type
- 5.5.2.2 Services
- 5.5.2.3 Technology
- 5.5.2.4 Application
- 5.5.2.5 Deployment
- 5.5.2.6 End User
- 5.5.3 United Kingdom
- 5.5.3.1 Type
- 5.5.3.2 Services
- 5.5.3.3 Technology
- 5.5.3.4 Application
- 5.5.3.5 Deployment
- 5.5.3.6 End User
- 5.5.4 Spain
- 5.5.4.1 Type
- 5.5.4.2 Services
- 5.5.4.3 Technology
- 5.5.4.4 Application
- 5.5.4.5 Deployment
- 5.5.4.6 End User
- 5.5.5 Italy
- 5.5.5.1 Type
- 5.5.5.2 Services
- 5.5.5.3 Technology
- 5.5.5.4 Application
- 5.5.5.5 Deployment
- 5.5.5.6 End User
- 5.5.6 Rest of Europe
- 5.5.6.1 Type
- 5.5.6.2 Services
- 5.5.6.3 Technology
- 5.5.6.4 Application
- 5.5.6.5 Deployment
- 5.5.6.6 End User
- 5.5.1 Germany
- 5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
- 5.6.1.1 Type
- 5.6.1.2 Services
- 5.6.1.3 Technology
- 5.6.1.4 Application
- 5.6.1.5 Deployment
- 5.6.1.6 End User
- 5.6.2 United Arab Emirates
- 5.6.2.1 Type
- 5.6.2.2 Services
- 5.6.2.3 Technology
- 5.6.2.4 Application
- 5.6.2.5 Deployment
- 5.6.2.6 End User
- 5.6.3 South Africa
- 5.6.3.1 Type
- 5.6.3.2 Services
- 5.6.3.3 Technology
- 5.6.3.4 Application
- 5.6.3.5 Deployment
- 5.6.3.6 End User
- 5.6.4 Sub-Saharan Africa
- 5.6.4.1 Type
- 5.6.4.2 Services
- 5.6.4.3 Technology
- 5.6.4.4 Application
- 5.6.4.5 Deployment
- 5.6.4.6 End User
- 5.6.5 Rest of MEA
- 5.6.5.1 Type
- 5.6.5.2 Services
- 5.6.5.3 Technology
- 5.6.5.4 Application
- 5.6.5.5 Deployment
- 5.6.5.6 End User
- 5.6.1 Saudi Arabia
6 Market Strategy
- 6.1 Demand-Supply Gap Analysis
- 6.2 Trade & Logistics Constraints
- 6.3 Price-Cost-Margin Trends
- 6.4 Market Penetration
- 6.5 Consumer Analysis
- 6.6 Regulatory Snapshot
7 Competitive Intelligence
- 7.1 Market Positioning
- 7.2 Market Share
- 7.3 Competition Benchmarking
- 7.4 Top Company Strategies
8 Company Profiles
- 8.1 IBM
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
- 8.2 Microsoft
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
- 8.3 Google
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
- 8.4 Amazon
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
- 8.5 Oracle
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
- 8.6 SAS Institute
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
- 8.7 Cognizant
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
- 8.8 Accenture
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
- 8.9 IQVIA
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
- 8.10 Optum
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
- 8.11 Clarivate
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
- 8.12 Palantir Technologies
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
- 8.13 Flatiron Health
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
- 8.14 Tempus
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
- 8.15 Medidata Solutions
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
- 8.16 BioXcel Therapeutics
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
- 8.17 Exscientia
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
- 8.18 BenevolentAI
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
- 8.19 Insilico Medicine
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
- 8.20 Atomwise
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis
9 About Us
- 9.1 About Us
- 9.2 Research Methodology
- 9.3 Research Workflow
- 9.4 Consulting Services
- 9.5 Our Clients
- 9.6 Client Testimonials
- 9.7 Contact Us
